10-Q/A 1 s109199_10qa.htm 10-Q/A

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A 

AMENDMENT NO. 1 TO FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 333-216054

 

AVRA MEDICAL ROBOTICS, INC.

(Exact name of registrant as specified in its charter)

 

Florida 47-3478854
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)

 

3259 Progress Drive, Suite 112A, Orlando, FL 32826

(Address of Principal Executive Offices)

 

(407) 956-2250

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large Accelerated Filer ☐ Accelerated Filer ☐
Non-accelerated filer ☐

Smaller reporting company ☒ 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares outstanding of the registrant’s common stock, $0.01 par value, as of November 13, 2017 was 20,644,746 shares.

 

 

 

 

Explanatory Note

 

This Quarterly Report on Form 10Q/A, Amendment No 1 to Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (the “Original Report”), is being filed to restate the condensed balance sheet of AVRA Medical Robotics, Inc. (“AVRA”) at September 30, 2017, the condensed statements of operations of AVRA for the three and nine months ended September 30, 2017 and the condensed statement of cash flows of AVRA for the nine months ended September 30, 2017 contained in the Original Report, to reflect the grant of 45,000 shares of common stock for services rendered, which was inadvertently not reflected in the Original Report.

 

TABLE OF CONTENTS

 

    Page
     
PART I – FINANCIAL INFORMATION 2
     
Item 1. Financial Statements 2
     
  Condensed Balance Sheets as of September 30, 2017 and December 31, 2016 (unaudited) 2
     
  Condensed Statements of Operations for the three and nine months ended September 30, 2017 and 2016 (unaudited) 3
     
  Condensed Statements of Cash Flows for the nine months ended June 30, 2017 and 2016 (unaudited) 4
     
  Notes to Condensed Financial Statements (unaudited) 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
     
Item 3. Quantitative Disclosures About Market Risks 14
     
Item 4. Controls and Procedures 14
     
PART II - OTHER INFORMATION 15
     
Item 1. Legal Proceedings 15
     
Item 1A. Risk Factors 15
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15
     
Item 3. Defaults Upon Senior Securities 15
     
Item 4. Mine Safety Disclosures 15
     
Item 5. Other Information 15
     
Item 6. Exhibits 15
     
SIGNATURES 16

  

 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

 AVRA MEDICAL ROBOTICS, INC.

  CONDENSED BALANCE SHEETS

  (UNAUDITED)  

 

   September 30, 2017   December 31, 2016 
         
ASSETS          
CURRENT ASSETS:          
Cash and cash equivalents  $520,855   $248,219 
Other prepaid expenses and deposit   1,682    465 
Total Current Assets   522,537    248,684 
           
EQUIPMENT   4,174     
Accumulated depreciation   (580)    
    3,594     
OTHER ASSETS          
Intellectual Property   43,548    43,548 
           
TOTAL ASSETS  $569,679   $292,232 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) CURRENT LIABILITIES:          
Accounts Payable  $1,450   $54,827 
Accrued expenses   187,716    90,588 
Due to majority shareholder       21,877 
Promissory Notes       480,000 
Total Current Liabilities   189,166    647,292 
           
STOCKHOLDERS’ EQUITY (DEFICIT)          
Preferred stock, 5,000,000 shares authorized, $.0001 par value, none issued or outstanding        
Common stock, 100,000,000 shares authorized, $.0001 par value, 20,644,746 and 19,000,000 issued and outstanding, respectively   2,064    1,900 
Stock subscriptions receivable   (81,185)    
Additional paid-in capital   1,564,707    128,088 
Accumulated Deficit   (1,105,073)   (485,048)
Total Stockholders’ Equity (Deficit)   380,513    355,060 
           
TOTAL LIABILITIES AND  STOCKHOLDERS’ EQUITY (DEFICIT)  $569,679   $(292,232)

 

The accompanying notes are an integral part of these financial statements.

 

2 

 

 

AVRA MEDICAL ROBOTICS, INC. 

 CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   Three Months   Three Months   Nine Months   Nine Months 
   Ended   Ended   Ended   Ended 
   September 30, 2017   September 30, 2016   September 30, 2017   September 30, 2016 
                 
REVENUES  $   $   $   $ 
                     
OPERATING EXPENSES                    
Research and Development   6,067    54,436    57,208    81,654 
General and Administrative   221,273    182,464    535,854    194,982 
Total Operating Expenses   227,340    236,900    593,062    276,636 
                     
OTHER INCOME AND (EXPENSES)                    
Interest Earned   8    12    38    14 
Interest Expense   (9,000)   (9,978)   (27,000)   (13,520)
Total Other Income and (Expenses)   (8,992)   (9,966)   (26,962)   (13,506)
                     
LOSS BEFORE INCOME TAXES   (236,332)   (246,866)   (620,024)   (290,142)
                     
PROVISION FOR INCOME TAXES                
                     
NET LOSS  $(236,332)  $(246,866)  $(620,024)  $(290,142)
                     
BASIC AND DILUTED LOSS PER SHARE  $(0.01)  $(0.01)  $(0.03)  $(0.02)
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING BASIC AND DILUTED   19,249,637    19,000,000    19,165,465    18,332,527 

 

The accompanying notes are an integral part of these financial statements.

 

3 

 

 

 AVRA MEDICAL ROBOTICS, INC. 

  CONDENSED STATEMENTS OF CASH FLOWS

   (UNAUDITED)  

 

   Nine Months   Nine Months 
   Ended   Ended 
   September 30, 2017   September 30, 2016 
         
CASH FLOWS FROM OPERATING ACTIVITIES          
Net Loss  $(620,024)  $(290,142)
Adjustments to reconcile net loss to net cash (used) provided in operating activities:          
Depreciation Expense   580     
Stock compensation expense   103,897    93,914 
Changes in operating assets and liabilities:          
Increase in prepaid expenses   (1,217)   (7,183)
Increase in accounts payable and accrued expenses   219,376    50,427 
Net Cash (Used) Provided in Operating Activities   (297,388)   (152,984)
           
INVESTING ACTIVITIES          
Purchase of Intellectual Property       (43,548)
Equipment acquisition   (4,174)    
Net Cash Used in Investing Activities   (4,174)   (43,548)
           
FINANCING ACTIVITIES          
Increase in Promissory Notes       480,000 
Increase (decrease) of shareholder loans   (21,877)   3,848 
Sale of common stock for cash   596,075    1,310 
Net Cash Provided by Financing Activities   574,198    485,158 
           
(DECREASE) IN CASH AND CASH EQUIVALENTS   272,636    288,626 
           
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD   248,219    100 
           
CASH AND CASH EQUIVALENTS  AT END OF PERIOD  $520,855   $288,726 
           
SUPPLEMENTAL INFORMATION OF NON-CASH          
INVESTING AND FINANCING ACTIVITIES          
Cash paid for interest  $   $ 
           
Noncash financing activities:          
Related party accrued expenses converted into common stock  $231,876   $ 
Related party note payable converted into common stock  $480,000   $ 

 

The accompanying notes are an integral part of these financial statements.

 

4 

 

 

AVRA MEDICAL ROBOTICS, INC.

 NOTES TO CONDENSED FINANCIAL STATEMENTS 

 (UNAUDITED)

 

NOTE 1 – CONDENSED FINANCIAL STATEMENTS

 

AVRA Medical Robotics, Inc. (the “Company” or “AVRA”) was incorporated as AVRA Surgical Microsystems, Inc. in the State of Florida on February 4, 2015. Effective November 5, 2015, the Company’s corporate name was changed to AVRA Medical Robotics, Inc. The Company was established to develop advanced medical surgical devices. The Company is structured to invest in four principal areas – surgical robotic systems, surgical tools, implantable devices and surgical robotic training.

 

In the opinion of the Company the accompanying unaudited condensed financial statements prepared in accordance with instructions for Form 10-Q, include all adjustments (consisting only of normal recurring accruals) which are necessary for a fair presentation of the results for the periods presented, Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that the condensed financial statements be read in conjunction with the Company’s S-1 Registration Statement (File No. 333-216054). The Balance Sheet as of December 31, 2016 was derived from audited financial statements as of that date. The results of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results to be expected for the full year.

 

Restatement of Financial Statements

 

The condensed balance sheet at September 30, 2017, the condensed statements of operations for the three and nine months ended September 30, 2017 and the condensed statement of cash flows for the nine months ended September 30, 2017 have been restated to reflect the grant of 45,000 shares of common stock for services rendered. The shares vested on the grant date and were valued at $1.25 per share.

 

The accompanying financial statements are prepared on the basis of accounting principles generally accepted in the United States of America (“GAAP”). The Company is a development-stage enterprise devoting substantial efforts to establishing a new business, financial planning, raising capital, and research into products which may become part of the Company’s product portfolio. The Company has not realized significant sales through September 30, 2017. A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and, even if planned principal operations have commenced, revenues are insignificant.

 

The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect. While management of the Company believes that it will be successful in its capital formation and planned operating activities, there can be no assurance that the Company will be able to raise additional equity capital, or be successful in the development and commercialization of the products it develops or initiates collaboration agreements thereon. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

5 

 

 

NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS

 

The Company does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, will have a material effect on the Company’s financial position, results of operations and cash flows.

 

NOTE 3 – Research collaboration agreement

 

Effective May 1, 2016, the Company entered into a Research Agreement (the “Research Agreement”) with the University of Central Florida (“UCF” or the “University”) for the development of a prototype surgical robotic device supporting minimal invasive surgical facial corrections.

 

The Agreement provides that the University will provide personnel to accomplish the objectives as stated in the Statement of Work over a period extending to September 30, 2017. Effective May 1, 2017, the research agreement with the University of Central Florida has been extended to September 30, 2019. No additional payments to the University were required.

 

The Company agreed to extend funding of $163,307 from AVRA’s existing funds.

 

In addition, AVRA has paid $43,548 for outright ownership of the University’s Intellectual Property resulting from the collaboration, which amount is shown as Intellectual Property. Management has assessed the carrying value of the asset and believes there has been no diminution of its value and accordingly, no adjustment is necessary.

 

The total cost to the Company is:

 

Research Expense -funded from existing funds   $ 163,307  
Acquisition of Intellectual Property Rights     43,548  
Total   $ 206,855  

 

At December 31, 2016, $125,202 had been paid under the Agreement. The balance of the amount owing to the University was fully paid on February 24, 2017 and April 7, 2017. Additionally, a $68,952 matching funds grant from the Florida High Tech Corridor Council (FHTCC) was approved on July 16, 2016 which will provide the University research funds in addition to the Company’s funding obligation to the University. The FHTCC research grant is subject to certain research obligations and action requirements which if not met may result in the loss of the FHTCC research funding which would require the Company to cover any resulting shortfall. The agreement further provides for the payment of a 1% royalty to the University in any year when the sales of products using the intellectual property exceeds $20,000,000.

 

NOTE 4 – ACCRUED EXPENSES

 

Accrued Expenses include $67,825 and $67,500 in accrued compensation to two officers at September 30, 2017 and three officers at December 31, 2016, respectively.

 

6 

 

 

NOTE 5 – PROMISSORY NOTES

 

During the year ended December 31, 2016, the Company borrowed $480,000 under 7.5% Convertible Promissory Notes (the “Notes”). The Notes were due September 30, 2017 and bear interest at 7.5%. The noteholders had agreed to extend the maturity to October 31, 2017. The notes were convertible into common stock of the Company at $0.50 per share in the event of a voluntary conversion on or before an optional prepayment or the maturity date, or (1) the lower of $0.50 or (2) a 20% discount to the effective price per share offering price in the event of a mandatory conversion upon consummation of a “Qualified Financing”, as defined in the Notes. The Company had pledged all assets as security for the notes. In the event of default, the notes would bear interest at 12% per annum.

 

Based upon the completion by the Company on September 30, 2017 of a private offering of 433,808 shares at a price of $1.25 per share (an aggregate of $542,260), a Qualified Financing occurred and the $480,000 principal amount of the Notes was converted into 960,000 shares of common stock. In addition, in lieu of accrued interest and in consideration for having extended the original maturity date of the Notes, on October 1, 2017, the noteholders were issued three-year warrants to purchase 144,000 shares of common stock at an exercise price of $1.25 per share.

 

Further, the Company borrowed $100,000 from an individual on May 16, 2016 under a note bearing interest at 5%. The note, along with accrued interest, was repaid on September 30, 2016.

 

NOTE 6 – INCOME TAXES

 

The Company’s deferred tax assets at September 30, 2017 and December 31, 2016 consist of net operating loss carry forwards of $1,048,808 and $485,048, respectively. Using a federal statutory tax rate of 35%, the valuation allowance balance as of September 30, 2017 and December 31, 2016 total $367,083 and $169,767, respectively. The increase in the valuation allowance balance for the nine months ended September 30, 2017 of $197,316 is entirely attributable to the net operating loss.

 

Due to the uncertainty of their realization, no income tax benefits have been recorded by the Company for these loss carry-forwards as valuation allowances have been established for any such benefits. The increase in the valuation allowance was the result of increases in the net operating losses discussed above. Therefore, the Company’s provision for income taxes is $0 for the three and nine months ended September 30, 2017 and 2016

 

At September 30, 2017 and December 31, 2016 the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. At September 30, 2017 and 2016 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.

 

The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.

 

7 

 

 

NOTE 7 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

The Company is authorized to issue up to 100,000,000 shares of common stock, $0.0001 par value per share plus 5,000,000 shares of preferred stock, par value $0.0001. On February 1, 2016 subscriptions were issued for 5,899,600 shares of common stock at $0.0001 per share (total $590). In February 2017, the Company raised an additional $135,000 from a private offering of 135,000 shares of common stock at a price of $1.00 per share made to three investors.

 

Effective April 1, 2017, the Company entered into Conversion Agreements with its Chairman/CEO and the Chief Financial Officer whereby each agreed to convert the amounts owing to them as of March 31, 2017 as compensation into common stock of the Company at a price of $2.00 per share. Furthermore, the Chief Financial Officer has agreed to convert any future amounts due as compensation per his Employment Agreement effective through August 1, 2017, into shares of common stock at $2.00 per share as such amounts are earned, and the Chairman/CEO has agreed to convert any future amounts in excess of $2,500 per month due as compensation through July 1, 2017, per his Employment Agreement, into shares of common stock at $2.00 per share as such amounts are earned. On April 1, 2017, 57,438 shares were issued under the agreement to convert compensation due to the Chairman/CEO and Chief Financial Officer. Both agreements were renewed upon their respective expirations. As of July 1, 2017, the Chairman/CEO agreed to convert any future amounts in excess of $2,500 per month due as compensation through December 31, 2017, per his Employment Agreement, into shares of common stock at $2.00 per share, as such amounts are earned. As of August 1, 2017, the Chief Financial Officer agreed to convert all cash payments due to the employee per his Employment Agreement, into shares of common stock using a price of $2.00 per share, as such amounts are earned.

 

On September 30, 2017, the Chairman/CEO and the Chief Financial Officer converted $117,000 of compensation owed into 58,500 common shares.

 

On September 30, 2017, the Company sold 433,808 shares of common stock at $1.25 per share for a total of $542,260; $461,075 was received in September with the balance of $81,185, collected subsequent. This amount is being reflected as stock subscriptions receivable on the balance sheet under the stockholders’ equity section.

 

In addition, on September 30, 2017, the promissory notes of $480,000 were converted into 960,000 shares of common stock. In lieu of accrued interest and in consideration for having extended the original maturity date of the Notes, on October 1, 2017, the noteholders were issued three-year warrants to purchase 144,000 shares of common stock at an exercise price of $1.25 per share. (see Note 5).

 

Holders are entitled to one vote for each share of common stock. No preferred stock has been issued.

 

8 

 

 

NOTE 8 – 2016 INCENTIVE STOCK PLAN

 

On August 1, 2016, the Company adopted its 2016 Incentive Stock Plan (the “Plan”). The Plan provides for the granting of options to employees, directors, consultants and advisors to purchase up to 3,000,000 shares of the Company’s common stock. The Board is responsible for administration of the Plan. The Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair market value per common share on the date of the grant.

 

On August 15, 2016, five-year options were granted to certain participants for the purchase of 1,702,000 shares at an exercise price of $0.10 per share. 1,000,000 shares vested immediately and the balance over three years.

 

On October 1, 2016, five-year options were granted to certain participants for the purchase of 856,000 shares at an exercise price of $0.15 per share.

 

As of January 1, 2017, an option for the purchase of 40,000 shares was made at an exercise price of $0.15 per share. All 40,000 shares vested immediately.

 

As of August 1, 2017, an additional five-year option for the purchase of 30,000 shares was made at an exercise price of $1.00. The shares vest over three years.

 

At September 30, 2017 and December 31, 2016 options representing 1,603,667 shares and 1,176,000 shares were vested or exercisable, respectively.

 

No options were exercised during the nine months ended September 30, 2017 or for the year ended December 31, 2016. Options for 56,250 shares were forfeited on June 30, 2017.

 

All options issued to-date expire after five years from the issue date. Except for the option for one million shares issued to the CEO and to the Company’s counsel for 40,000 shares that vested immediately, all the options issued to date vest over three years.

 

Stock options are accounted for in accordance with FASB ASC Topic 718, Compensation –Stock Compensation, with option expense amortized over the vesting period based on the Black-Scholes option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of expense. During the three and nine months ended September 30, 2017 and 2016 $11,910 and $47,632, respectively, has been recorded as stock-based compensation and classified in general and administrative expense on the Statement of Operations. The total amount of unrecognized compensation cost related to non-vested options was $22,419 as of September 30, 2017. This amount will be recognized over a weighted average period of 2.0 years.

 

The grant date fair value of options granted during the year of 2016 were estimated on the grant date using the Black-Scholes model with the following assumptions: expected volatility of 181%, expected term of 1.9 years, risk-free interest rate of 2.00% and expected dividend yield of 0% for the options granted on August 15, 2016 with an exercise price of $0.10 per share and; expected volatility of 73.64%, expected term of 2.0 years, risk-free interest rate of 2.00% and expected dividend yield of 0% for the options granted on October 1, 2016 with an exercise price of $0.15 per share. For options granted January 1, 2017, the following factors were used; volatility 36.18%;

 

9 

 

 

NOTE 8 – INCENTIVE STOCK PLAN (CONTINUED)

 

risk-free interest rate of 2.00%, dividend yield of 0% and expected life of 2.3 years. For options granted August 1, 2017, the following factors were used: volatility 63.05%; risk-free interest rate of 2.00%, dividend yield of 0% and expected life of 2.8 years.

 

Expected volatility is based on the average of the historical volatility of the stock prices of a blend of five publicly traded companies operating in a similar industry as that of the Company. The risk-free rate is based on the rate of U.S Treasury zero-coupon issues with a remaining term equal to the expected life of the options. The Company uses historical data to estimate pre-vesting for feature rates.

 

During the three months ended September 30, 2017, 45,000 shares of common stock were granted under the Plan to two individuals for services rendered. The shares vested on the grant date and were valued at $1.25 per share. This resulted in a charge to stock compensation expense of $56,250.

 

NOTE 9 – EMPLOYMENT AGREEMENTS

 

On July 1, 2016, the Company entered into an Employment Agreement with its Chairman and Chief Executive Officer. The agreement provides for an annual salary of $120,000 per year, increasing to $180,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, and becoming fully vested on August 15, 2016.

 

On August 1, 2016, the Company entered into a one-year Employment Agreement with its Chief Financial Officer. The agreement provides for an annual salary of $108,000 per year. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary. The options are to be surrendered and cancelled if the Agreement is terminated. The Agreement has expired but its compensation terms continue in effect as long as the employee remains employed by the Company.

 

On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary.

 

Further, on July 1, 2016, the Company entered into Indemnification Agreements with the Chairman and Chief Executive Officer, and on August 1, 2016 the Chief Financial Officer and the Vice-President of Global Business Development providing for the Company to indemnify the individuals for all expenses, judgments, etc. incurred while serving in various capacities with the Company.

 

10 

 

 

NOTE 10 – EARNINGS PER SHARE

 

Basic earnings per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. For the three and nine months ended September 30, 2017 and 2016 the potential conversion of the Promissory Notes into common stock was excluded from the computation of fully-diluted loss per share as the effect was anti-dilutive. Further, the potential exercise of stock options has been excluded from the computation of loss per share as the effect was anti-dilutive.

 

NOTE 11 – LEASE COMMITMENT

 

The Company occupies office and laboratory space in Orlando, Florida under a lease agreement expiring July 31, 2017. Effective August 1, 2017, the agreement was amended to provide for additional space and to extend the lease term to July 31, 2018. The amended agreement provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $457.

 

NOTE 12 – SUBSEQUENT EVENTS

 

In connection with the September 30, 2017 mandatory conversion of $480,000 in principal amount of 7.5% Convertible Promissory Notes into 960,000 shares of common stock (see Note 5), on October 1, 2017, the noteholders were issued three-year warrants to purchase 144,000 shares of common stock at an exercise price of $1.25 per share, in lieu of accrued interest and in consideration for having extended the original maturity date of the notes.

 

The Company has evaluated subsequent events through the date that the financial statements were issued and determined that there were no other subsequent events requiring adjustment to or disclosure in the financial statements.

 

11 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

When used in this report, unless otherwise indicated, the terms “AVRA,” “the Company,” “we,” “us” and “our” refer to AVRA Medical Robotics, Inc.

 

Note Regarding Forward Looking Statements

 

This report contains forward-looking statements that reflect our current views about future events. We use the words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

 

Introduction

 

AVRA is currently developing a prototype for skin resurfacing in partnership with the University of Central Florida, recognized particularly for its work in the area of medical robotics research and design, focusing on the guidance systems which will allow AVRA’s medical robotic system to handle any currently available “tool” in the market.

 

The financial statements appearing elsewhere in this statement have been prepared assuming the Company will continue as a going concern. The company was recently formed and has not established sufficient operations or revenues to sustain the company. These conditions raise substantial doubt about the company’s ability to continue as a going concern.

 

Results of Operations

 

Three months ended September 30, 2017, as compared to three months ended September 30, 2016

 

General. During the three months ended September 30, 2016, our operations were limited to organizational and planning activities and various research initiatives.

 

Revenues. We had no revenues during the three months ended September 30, 2017 or the three months ended September 30, 2016.

 

Research and Development Expenses. Research and development expenses during the three months ended September 30, 2017 were $6,067, as compared to $54,436 for the three months ended September 30, 2016. The decrease in research and development expenses from the 2016 quarter to the 2017 quarter, reflects the completion of the first phase of research by the University of Central Florida. The Company is continuing development work on its prototype at its facilities at the University of Central Florida’s incubator.

 

General and Administrative Expenses. We incurred $221,273 in general and administrative expenses during the three months ended September 30, 2017, as compared to $182,464 for the three months ended September 30, 2016. The increase is attributable to the beginning of payment of compensation for the management staff, legal and other professional expenses related to the registration of the Company’s common stock with the Securities and Exchange Commission and stock-based compensation expense on the Company’s 2016 Stock Incentive Plan.

 

Other Expenses. We incurred a net $8,992 of other expenses during the three months ended September 30, 2017, as compared to $9,966 for the three months ended September 30, 2016. Other expenses principally represent net interest expense on the Company’s $480,000 in principal amount of 7.5% Convertible Promissory Notes (the “Notes”), which were mandatorily converted into shares of common stock at the end of the 2017 quarter.

 

Net Loss. We incurred a net loss of $(236,332) during the three months ended September 30, 2017, as compared to a net loss of $(246,866) for the three months ended September 30, 2016.

 

12 

 

 

Nine months ended September 30, 2017, as compared to nine months ended September 30, 2016

 

General. During the nine months ended September 30, 2016, our operations were limited to organizational and planning activities and research activities under the agreement with the University of Central Florida.

 

Revenues. We had no revenues during the nine months ended September 30, 2017 or the nine months ended September 30, 2016.

 

Research and Development Expenses. Research and development expenses during the nine months ended September 30, 2017 were $57,208, compared to $81,654 for the nine months ended September 30, 2016. The decrease in research and development expenses from the 2016 period to the 2017 period, reflects the completion of the first phase of research by the University of Central Florida.

 

General and Administrative Expenses. We incurred $535,854 in general and administrative expenses during the nine months ended September 30, 2017, compared to $194,982 for the nine months ended September 30, 2016. The increase is attributable to the beginning of payment of compensation for the management staff, legal and other professional expenses related to the registration of the Company’s common stock with the Securities and Exchange Commission and stock-based compensation expense on the Company’s 2016 Stock Incentive Plan.

 

Other Expenses. We incurred a net $26,962 of other expenses during the nine months ended September 30, 2017, as compared to $13,506 for the nine months ended September 30, 2016. Other expenses principally represent net interest expense on the Company’s $480,000 in principal amount of Notes (the “Notes”), which were mandatorily converted into shares of common stock at the end of the 2017 period.

 

Net Loss. We incurred a net loss of $(620,024) during the nine months ended September 30, 2017, as compared to a net loss of $(290,142) for the nine months ended September 30, 2016.

 

Liquidity and Capital Resources

 

The Company expects to require substantial funds for research and development, to continue to develop its initial proposed medical robotic system. The Company plans to meet its operating cash flow requirements by raising additional funds from the sale of our securities and, if possible on favorable terms, by entering into development partnerships to assist the Company with its technology development activities.

 

During the period from inception (February 4, 2015) through December 31, 2016, the Company raised $1,900 from private offerings of its common stock and a private offering of $480,000 in principal amount of the Notes. In February 2017, the Company raised an additional $135,000 from a private offering of 135,000 shares of common stock at a price of $1.00 per share made to three investors. On September 30, 2017, the Company sold 433,808 shares of stock in a private offering at a price of $1.25 per share or an aggregate of $542,260 of which $461,075 was collected prior the quarter end. As a result of the completion of that offering, the $480,000 in principal amount of the Notes converted into 960,000 shares of our common stock.

 

While we have been successful in raising funds to fund our operations since inception and we believe that we will be successful in obtaining the necessary financing to fund our operations going forward, we do not have any committed sources of funding and there are no assurances that we will be able to secure additional funding. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern; however, if the efforts noted above are not successful, it would raise substantial doubt about the Company’s ability to continue as a going concern. If we cannot obtain financing, then we may be forced to further curtail our operations or consider other strategic alternatives. Even if we are successful in raising the additional financing, there is no assurance regarding the terms of any additional investment and any such investment or other strategic alternative would likely substantially dilute our current shareholders.

 

13 

 

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Item 3. Quantitative Disclosures About Market Risks.

 

As a “smaller reporting company,” we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures.

 

Management’s Report on Disclosure Controls and Procedures

 

Our Chief Executive Officer and our Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, as of September 30, 2017 to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms adopted by the Securities and Exchange Commission (the “SEC”), including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (our Principal Executive Officer) and our Chief Financial Officer (our Principal Financial and Accounting Officer), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2017, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified in the “Risk Factors” section of our Registration Statement on Form S-1 (File No. 333-216054).

 

Our Chief Executive Officer and Chief Financial Officer do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officer has determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Changes in Internal Controls Over Financial Reporting

 

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

14 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Not Applicable.

 

Item 1. A. Risk Factors.

 

See the section of our prospectus entitled “Risk Factors” in our Registration Statement on Form S-1 (File No. 333-216054), declared effective by the Securities and Exchange Commission on July 31, 2017.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Effective September 30, 2017, two executive officers of the Company converted accrued but unpaid compensation of $117,000 owed to them as of such date, into an aggregate of 58,500 shares of our common stock.

 

In connection with the September 30, 2017, mandatory conversion of the Company’s $480,000 in principal amount of 7.5% Convertible Promissory Notes (the “Notes”) into 960,000 shares of common stock, on October 1, 2017, the noteholders were issued three-year warrants to purchase 144,000 shares of common stock at an exercise price of $1.25 per share in lieu of accrued interest and in consideration for having extended the original maturity date of the Notes.

 

During the three months ended September 30, 2017, 45,000 shares of common stock were granted under our 2016 Incentive Stock Plan to two individuals for services rendered. The shares vested on the grant date and were valued at $1.25 per share.

 

All of the above securities were issued pursuant to the exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) of the Securities Act and Regulation D and Rule 701 thereunder.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

 

Exhibit No.   Description of Exhibit
     
31.1   Section 302 Certification by Chief Executive Officer
     
31.2   Section 302 Certification by Chief Financial Officer
     
32.1   Section 906 Certification by Chief Executive Officer
     
32.2   Section 906 Certification by Chief Financial Officer

 

15 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  AVRA MEDICAL ROBOTICS, INC.
     
Dated: February 28, 2018 By: /s/ Barry F. Cohen
    Barry F. Cohen, Chief Executive Officer
    (Principal Executive Officer)
     
Dated: February 28, 2018 By: /s/ A. Christian Schauer
    A. Christian Schauer, Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

16